MedTrace Logo

Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine for Postoperative Analgesia

NCT06949852 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2025-04-29

No results posted yet for this study

Summary

Evaluation of safety and efficacy of Nalbuphine versus Morphine patient controlled intravenous analgesia (PCIA) for the treatment of postoperative analgesia

Conditions

  • Postoperative Analgesia

Interventions

DRUG

Nalbuphine Hydrochloride Injection

PCIA，The lockout interval is set at 10 minutes, with no background infusion.

DRUG

Morphine Hydrochloride Injection

PCIA，The lockout interval is set at 10 minutes, with no background infusion.

Sponsors & Collaborators

  • Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-07
Primary Completion
2025-06-30
Completion
2026-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06949852 on ClinicalTrials.gov